Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC ARV-110 at ASCO 2018 Genitourinary Cancers Symposium. Arvinas Announces Research Collaboration and License Agreement with Pfizer Inc. for the Discovery and Development of Protein Degradation Drug Candidates. Arvinas Nominates Oral Clinical Candidate for Estrogen Receptor Degrader Program. Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC ARV-110 at ASCO 2018 Genitourinary Cancers Symposium.

G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. We are advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications.

Creating a new generation of small molecule protease inhibitors. KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs. KalVista continues to investigate additional proteases as potential therapeutic targets to fully exploit its research expertise and expand its portfolio. KalVista Pharmaceuticals Reports Fiscal Third Quarter Results.

Product Designer and User Experience Consultant. I am a seasoned, freelance, independent product designer and user experience consultant with 19 years of experience based in Boston, MA. I design useful, usable, and beautiful user experiences for mobile and desktop applications and specialize in making complex consumer and enterprise software easy to use. Consulting product designer for Apptopia.

Aims to solve critical prevention, diagnostic, and treatment and rehabilitation challenges facing the Lyme disease field by bringing together diverse researchers and scientists in a hackathon environment. This effort is led by the Dean Center for Tick Borne Illness. And is sponsored by the Bay Area Lyme Foundation.

Is a co-founder and Partner of Longwood Fund. He has co-founded and led a number of successful biomedical companies, including FlexPharma, Verastem, Alnara Pharmaceuticals, OvaScience, Sirtris, Alnylam Pharmaceuticals, Acceleron Pharmaceuticals, and Momenta Pharmaceuticals. Is a founder, Portfolio Manager, and Managing Director at RA Capital, a. Crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies.